# A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis

> **NCT01840605** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 303 (actual)

## Conditions studied

- Dermatitis
- Atopic

## Interventions

- **DRUG:** Bepotastine besilate
- **DRUG:** ketotifen fumarate

## Key facts

- **NCT ID:** NCT01840605
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01840605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01840605, "A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01840605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*